Values as of: 2024-11-13
COMMON STOCK | Biotechnology |
Last Closing
USD 1.71Change
+0.20 (+13.25)%Market Cap
USD 0.09BVolume
0.18MAnalyst Target
USD 9.28Verdict
Verdict
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Company Website : https://www.inflarx.de
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+4.61 (+0.94%) |
USD 121.60B |
| REGN | Regeneron Pharmaceuticals Inc |
-16.67 (-2.03%) |
USD 92.70B |
| ARGX | argenx NV ADR |
+5.40 (+0.91%) |
USD 35.81B |
| ALNY | Alnylam Pharmaceuticals Inc |
-4.35 (-1.62%) |
USD 34.69B |
| BGNE | BeiGene Ltd |
+1.81 (+0.93%) |
USD 22.85B |
| MRNA | Moderna Inc |
-1.33 (-3.06%) |
USD 21.00B |
| UTHR | United Therapeutics Corporatio.. |
-0.42 (-0.10%) |
USD 16.70B |
| RPRX | Royalty Pharma Plc |
-0.15 (-0.58%) |
USD 16.11B |
| INCY | Incyte Corporation |
-0.10 (-0.12%) |
USD 14.67B |
| SMMT | Summit Therapeutics PLC |
-1.29 (-6.21%) |
USD 13.75B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| XEG:CA | iShares S&P/TSX Capped En.. | 5.08 % | 0.61 % |
+0.15 (+0.25%) |
CAD 1.49B |
| XMD:CA | iShares S&P/TSX Completio.. | 2.05 % | 0.61 % |
-0.03 (0.25%) |
CAD 0.23B |
| VSS | Vanguard FTSE All-World e.. | 0.30 % | 0.12 % |
-0.60 (0.25%) |
USD 8.81B |
| ENY | 0.00 % | 0.66 % |
N/A |
N/A | |
| FQC:CA | 0.00 % | 1.01 % |
N/A |
N/A | |
| HEE:CA | 0.00 % | 0.84 % |
N/A |
N/A | |
| SCHC | Schwab International Smal.. | 0.00 % | 0.12 % |
-0.26 (0.25%) |
N/A |
| ZJO:CA | 0.00 % | 0.60 % |
N/A |
N/A | |
| BREA:CA | Brompton Sustainable Real.. | 0.00 % | 0.00 % |
+0.07 (+0.25%) |
CAD 0.02B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 4.91% | 64% | D | 56% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 4.91% | 63% | D | 52% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 17.93% | 62% | D | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 17.93% | 62% | D | 59% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -26.29% | 63% | D | 34% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -26.29% | 62% | D | 32% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -6.20% | 38% | F | 26% | F | ||
| Dividend Return | -6.20% | 38% | F | 25% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 72.95% | 49% | F | 28% | F | ||
| Risk Adjusted Return | -8.50% | 38% | F | 30% | F | ||
| Market Capitalization | 0.09B | 44% | F | 38% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total earnings in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
